Industry Focus
Healthcare: The Crazy Back-Story To Sarepta Therapeutics' Game-Changing Approval
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:20:12
- Mas informaciones
Informações:
Sinopsis
Hit or miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy.
